A Phase 2/3, Double-Blind, Randomized, Placebo- Controlled, Safety and Efficacy Trial of BHV-3000 (rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)

Grants and Contracts Details

StatusFinished
Effective start/end date12/2/22 → 11/15/23

Funding

  • Biohaven Pharmaceuticals Incorporated: $12,119.00